Why are Ansell shares on investors' radars today?

Management sees the deal growing sales and earnings.

| More on:
Health professional putting on gloves.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Ansell Ltd (ASX: ANN) shares are in focus today after the company announced it finalised a major acquisition.

The purchase was made for all of the assets in US-listed entity Kimberly-Clark Corporation (NYSE: KMB)'s personal protective equipment (PPE) business – a deal Ansell initially announced on 8 April 2024.

Despite the completion of this major acquisition, Ansell shares remain steady at $25.90 per share at the time of writing, flat with the previous close of $25.91 apiece. Here's a closer look.

Ansell shares on radar after transaction

Kimberly-Clark is a US consumer goods giant, holding over 175 brands under its banner. Many are household names – Kleenex tissues and Huggies diapers are two examples.

It has a market capitalisation of US$47.8 billion at the time of writing.

The rationale behind the deal was to expand Ansell's product portfolio and market position. The $970 million transaction will see it acquire brands like Kimtech and KleenGuard – both used for anti-contamination against bacteria and viruses.

It also includes several manufacturing assets used in the production of gloves, masks, apparel, and eyewear.

Financial implications

The deal was finalised today after Ansell secured long-term debt financing to settle the balance.

It raised US$377 million via the United States Private Placement (USPP) market. The other portion of the deal was funded through a fully underwritten institutional placement of approximately 17.8 million new Ansell shares on 8 April, where it raised $400 million at $22.45 per share.

Since that date, these investors have made a 15% return on their money as I write.

The new debt facility announced today will replace previous instruments Ansell was using to fund its growth. As such, management noted this should provide Ansell with financial stability going into FY 2025:

The USPP proceeds replace the previously announced fully committed bridge facility which will no longer need to be drawn, with maturities on the notes issued ranging from 5 to 12 years and providing Ansell with long term funding certainty going into FY25.

Outlook for Ansell shares

Despite the size and potential impact of the acquisition, Ansell shares have not seen immediate movement in early trade on Tuesday.

Investors might be taking a wait-and-see approach, considering the complexities and integration efforts associated with such a significant purchase.

But analysts appear to be optimistic about the deal's long-term benefits. According to CommSec, Anshell shares are rated as a moderate buy, with 6 buy and 6 hold recommendations, respectively.

Ansell's management also expects the acquisition to be beneficial. It expects revenues and earnings per share (EPS) to grow directly as a result of the move. We will just have to wait and see if this is positive for Ansell shares or not.

The company's full-year results for FY 2024 are set to be released on 20 August, per the announcement.

In the last 12 months, Ansell shares have slipped over 4.5% into the red. This year to date, the stock has lifted into the green following a 6% return in the past month of trade.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ansell. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Green stock market graph with a rising arrow symbolising a rising share price.
Opinions

3 ASX shares tipped to climb over 100% in 2026

Analysts expect steep gains this year.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Opinions

4DMedical shares crash 20% this week: Should investors cut their losses on the once-booming stock?

The shares are now down 6.61% for the year to date.

Read more »

A woman researcher holds a finger up in happiness as if making the 'number one' sign with a graphic of technological data and an orb emanating from her finger while fellow researchers work in the background.
Healthcare Shares

Top broker tips 57% upside for beaten-down Telix shares

A leading broker expects a big rebound in Telix shares in 2026.

Read more »

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
Healthcare Shares

Here's why Anteris shares are in a trading halt today

The company is undertaking a US$300m capital raising.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Telix shares in focus as the company meets guidance

More good news from the drug developer.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

What are the healthcare stocks where RBC Capital Markets thinks you can make money?

The top buys in the sector, listed.

Read more »

A sad looking scientist sitting and upset about a share price fall.
Healthcare Shares

Polynovo shares fall despite yesterday's upbeat update. Here's what investors are watching

Polynovo shares slide after a solid update as investors wait for clearer growth signals.

Read more »

Woman flexes muscles after donating blood.
Healthcare Shares

Check out this CSL share price forecast for 2026. It's hard to believe!

RBC Capital Markets thinks CSL is a bargain at current levels.

Read more »